Genocea Biosciences (GNCA) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Genocea Biosciences (GNCA) PT Lowered to $2 at Cowen
February 15, 2018 3:00 PM ESTCowen lowered its price target on Genocea Biosciences (NASDAQ: GNCA) to $2.00 (from $5.00) while maintaining a Outperform rating.
Analyst Phil Nadeau commented, "Genocea reported Q4 financials including a net loss of $11MM and a pro-forma cash balance of $64MM. Meanwhile, lead... More
